Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Within 21 days of treatment initiation:\r\nHemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 8 g/dL (5.0 mmol/L)
Hemoglobin >= 9 g/dL (5.6 mmol/L)
Hemoglobin ? 8.0 g/dL (4.96 mmol/L)
SAFETY RUN-IN: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
RANDOMIZED PHASE II CLINICAL TRIAL: Within 10 days of registration: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin ? 9 g/dL or ? 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L.
Hemoglobin >= 9.0 g/dL (5.58 mmol/L)
Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9.0 g/dL (1.4 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
At time of registration and within 4 weeks prior to initiating on-protocol treatment: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Within 10 days prior to the start of study treatment: Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
Hemoglobin >= 8 g/dL or >= 5.0 mmol/L within 21 days of treatment initiation
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation
Hemoglobin 8.0 g/dL (5.0 mmol/L)
Within 7 days of registration: Hemoglobin >= 9.0 g/gL or >= 5.6 mmol/L, without recent transfusion
Hemoglobin ?9.0 g/dL (?5.6 mmol/L);.
Hemoglobin >= 7 g/dL or >= 5.6 mmol/L within 14 days prior to registration
Hemoglobin >= 9 g/dL (5.58 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Performed 28 days prior to study registration up to the first dose of study drug: hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Performed within 14 days (+3 working days) of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Performed within 14 days of treatment initiation: Hemoglobin >= 8 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L except in cases of marrow infiltration by lymphoma
Hemoglobin >= 9 g/dL (5.58 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin < 9 g/dL (5.6 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9.0 g/dL (1.4 mmol/L)
Performed within 28 days prior to study registration up to the first dose of study drug: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Performed within 10 days of treatment initiation; hemoglobin ? 9 g/dL or ? 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Magnesium < 1.4 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin ? 9 g/dL or ? 5.6 mmol/L within 7 days of treatment initiation
Hemoglobin ? 9g/dL or ? 5.6 mmol/L
Hemoglobin >= 8 g/dL or >= 4.96 mmol/L
Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
Magnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L
Within 30 days prior to treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L; transfusions permitted
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL (5.58 mmol/L)
Hemoglobin greater than 8.0 g/dL (= 80 g/L or 4.9 mmol/L)
Hemoglobin ?9 g/dL or ?5.6 mmol/L
Hemoglobin >=9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin ?9 g/dL or ?5.6 mmol/L- without qualifications
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin ? 8.0 g/dL (4.96 mmol/L)
Hemoglobin < 8.5 g/dL (< 5.3 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 14 days prior to registration
Within 14 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Performed within 28 days of radiation therapy: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 28 days of treatment initiation
Hemoglobin >= 9 g/dL (or >= 5.6 mmol/L)
Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L (labs should be performed within 14 days of treatment initiation)
Hemoglobin >= 9 g/dL (5.6 mmol/L) (tested within 14 days prior to registration)\r\n* Subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL (5.6 mmol/L); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 9 g/dL (5.6 mmol/L)
Hemoglobin ?8.0 g/dL (?4.96 mmol/L)
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin ? 9 g/L (?5.6 mmol/L).
Hemoglobin ? 8.0 g/dL (4.96 mmol/L)
Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL OR >= 5.6 mmol/L
Bone Marrow: Absolute neutrophil count ANC ? 1,500/mm3 (1.5 × 109/L); Platelets ? 100,000/mm3 (100 × 109/L); Hemoglobin ? 9.5 g/dL (1.4 mmol/L). Subjects with hemoglobin ? 9.5 g/dL (1.4 mmol/L) following transfusion are eligible;
Hemoglobin ? 9 g/dL or ? 5.6 mmol/L
Hemoglobin >= 10 g/dL (6.2 mmol/L)
Hemoglobin < 9 g/dL (5.6 mmol/L)
Performed within 10 days of treatment initiation: Hemoglobin >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin (Hgb) >= 9 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L
Hemoglobin >= 9 g/dL (5.6 mmol/L) (evaluated within 28 days of randomization); subjects may not have had a transfusion within 7 days of screening assessment
Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L, performed within 10 days of treatment initiation
Hemoglobin > 5.6 mmol/L (9 g/dL) at the screening visit
Hemoglobin >= 8.5 g/dL or >= 5.6 mmol/L